Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31631861 | 0.82 | TLR8 (0.48) | TLR8KDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL9157534 | 0.82 | NPC1 (0.34) | LMNACYP1A2 | |
| Water SCHEMBL29515280 | 0.79 | NPC1 (0.33) | CYP1A2 | |
| SCHEMBL1143403 | 0.75 | ALDH1A1 (0.40) | TLR8KDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL27929409 | 0.75 | TLR8 (0.44) | TLR8KDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL30420099 | 0.75 | ALDH1A1 (0.40) | TLR8KDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL2494234 | 0.75 | ALDH1A1 (0.40) | TLR8KDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL12368143 | 0.75 | ALDH1A1 (0.40) | TLR8KDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL22862786 | 0.75 | — | — | |
| SCHEMBL7048553 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662161-B2 | Pyrimidines and uses thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662161-B2 | Pyrimidines and uses thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180215720-A1 | PYRIMIDINES AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-08-02 | — | — | US | disclosed |
| US-20180215720-A1 | PYRIMIDINES AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-08-02 | — | — | US | disclosed |
| US-20180215720-A1 | PYRIMIDINES AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-08-02 | — | — | US | disclosed |
| EP-0901474-B1 | ARYL PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | disclosed |
| EP-1321169-A1 | Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament | Biofrontera Pharmaceuticals AG (DE) | 2003-06-25 | — | — | EP | disclosed |
| CN-1109675-C | Aryl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2003-05-28 | — | — | CN | disclosed |
| US-5958934-A | 5-HT 2B ANTAGONIST | SYNTEX (U.S.A.) INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5952331-A | SELECTIVE 5HT2B ANTAGONISTS; SEROTONIN RECEPTOR ANTAGONIST; TREATING DISORDERS OF THE GASTROINTESTINAL TRACK, RESTENOSIS, ASTHMA AND OBSTRUCTIVE AIRWAY DISEASE, PROSTATIC HYPERPLASIA, GENERALIZED ANXIETY, PANIC DISORDER | SYNTEX (USA) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| CN-1223641-A | Aryl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 1999-07-21 | — | — | CN | disclosed |
| EP-0901474-A1 | ARYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| US-5863924-A | Aryl pyrimidine derivatives | SYNTEX (U.S.A.) INC. (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1997044326-A1 | ARYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662161-B2 | Pyrimidines and uses thereof | TYMS, DPYD, TYMP | TLR8 1078/4885KDM4E 2162/4885ALDH1A1 1203/4885 |
| US-20180215720-A1 | PYRIMIDINES AND USES THEREOF | TYMS, DPYD, TYMP | TLR8 1078/4885KDM4E 2162/4885ALDH1A1 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.